This systematic review assesses the safety and effectiveness of low-dose oral continuous combined hormone therapy (cc-HT) for managing climacteric symptoms in postmenopausal women. It finds that low-dose cc-HT effectively alleviates symptoms and prevents bone loss with a favorable safety profile, showing no increased risks for cardiovascular diseases or breast cancer.
This review evaluates bioidentical hormone therapy (BHT) for managing menopausal symptoms, comparing it to conventional hormone replacement therapy (HRT). While BHT may alleviate symptoms for some, evidence supporting its efficacy and safety is limited, and there is no clear advantage over traditional HRT. The review also highlights concerns with individualized
This study evaluated clomiphene citrate (CC) for safety in male patients with infertility or hypogonadism. Over 12 months, it found that CC significantly increased testosterone without affecting PSA or haematocrit levels. The study included 77 men aged 22-51, all treated with 50 mg daily or every other day. CC showed
The article on PubMed discusses the safety of Clomiphene Citrate, a fertility treatment. It provides an overview of the drug’s effectiveness and the potential risks associated with its use. The study highlights the safety profile, including side effects, and reassures clinicians about its use for women seeking treatment for infertility.
